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Background
Congenital infection with human cytomegalovirus (CMV) is a major cause of mor-
bidity and mortality. In an uncontrolled study published in 2005, administration of 
CMV-specific hyperimmune globulin to pregnant women with primary CMV infec-
tion significantly reduced the rate of intrauterine transmission, from 40% to 16%.
Methods
We evaluated the efficacy of hyperimmune globulin in a phase 2, randomized, 
placebo-controlled, double-blind study. A total of 124 pregnant women with pri-
mary CMV infection at 5 to 26 weeks of gestation were randomly assigned within 
6 weeks after the presumed onset of infection to receive hyperimmune globulin or 
placebo every 4 weeks until 36 weeks of gestation or until detection of CMV in 
amniotic fluid. The primary end point was congenital infection diagnosed at birth 
or by means of amniocentesis.
Results
A total of 123 women could be evaluated in the efficacy analysis (1 woman in the 
placebo group withdrew). The rate of congenital infection was 30% (18 fetuses or 
infants of 61 women) in the hyperimmune globulin group and 44% (27 fetuses or 
infants of 62 women) in the placebo group (a difference of 14 percentage points; 
95% confidence interval, −3 to 31; P = 0.13). There was no significant difference 
between the two groups or, within each group, between the women who transmit-
ted the virus and those who did not, with respect to levels of virus-specific antibod-
ies, T-cell–mediated immune response, or viral DNA in the blood. The clinical 
outcome of congenital infection at birth was similar in the two groups. The number 
of obstetrical adverse events was higher in the hyperimmune globulin group than 
in the placebo group (13% vs. 2%).
Conclusions
In this study involving 123 women who could be evaluated, treatment with hyper-
immune globulin did not significantly modify the course of primary CMV infection 
during pregnancy. (Funded by Agenzia Italiana del Farmaco; CHIP ClinicalTrials.gov 
number, NCT00881517; EudraCT no. 2008-006560-11.)
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Every year, approximately 0.6% of all newborns in the United States and the European Union are congenitally infected 
with human cytomegalovirus (CMV).1,2 Approxi-
mately 20% of these infected newborns are 
symptomatic at birth or will have sequelae such 
as sensorineural hearing loss, cognitive defects, 
and motor defects.3 Primary CMV infection that 
develops in a woman during pregnancy confers 
the highest risk of congenital infection and dis-
ease.4 Identification of pregnant women with pri-
mary CMV infection is feasible by means of de-
tection of virus-specific IgM and low IgG avidity. 
However, the unavailability of a therapeutic in-
tervention of proven efficacy in the case of docu-
mented maternal infection has been considered 
to be a major obstacle to the implementation of 
routine serologic screening of pregnant women.
In 2005, a nonrandomized study showed that 
when CMV-specific hyperimmune globulin was 
administered to pregnant women with primary 
infection, the rate of mother-to-fetus transmission 
decreased significantly, from 40% to 16% (P = 0.04), 
and the risk of congenital disease also decreased 
significantly, from 50% to 3% (P<0.001).5 Other 
nonrandomized studies have shown a decrease 
in the number of congenitally infected infants 
born to mothers who had been treated with 
hyperimmune globulin or improved outcomes 
in CMV-infected infants.6-9 We designed the 
current randomized, controlled clinical trial to 
verify the previously reported efficacy of CMV-
specific hyperimmune globulin in preventing 
fetal infection.10
Me thods
Study Oversight
The Congenital HCMV Infection Prevention (CHIP) 
trial was a phase 2, double-blind, placebo-con-
trolled, parallel-group trial. We conducted the 
trial at 11 centers in Italy. The study, which was 
supported entirely by Agenzia Italiana del Farma-
co in Rome,11 was approved by the ethics com-
mittees at each participating center. Participants 
provided written informed consent before study 
entry. A contract research organization (Clinical 
Research Technology, Salerno, Italy) was respon-
sible for the regulatory aspects of the study, veri-
fication of source documents, and monitoring of 
safety.
Study End Points
The primary end point was the number of infected 
fetuses or newborns of mothers who received 
treatment with hyperimmune globulin as com-
pared with the number of infected fetuses or new-
borns of mothers who received placebo. Second-
ary end points included CMV DNA level, response 
to the study drug as assessed by means of an 
enzyme-linked immunosorbent assay (ELISA) and 
measurements of neutralizing antibodies, lym-
phocyte subpopulations, and CMV-specific T-cell 
response; virologic and immunohistologic find-
ings in placentas; ultrasonographic findings in 
fetuses; clinical outcomes of congenital CMV in-
fection within the first 2 weeks of life; and safety 
of CMV-specific hyperimmune globulin. Details 
of the study design are provided in the protocol 
and the Supplementary Appendix, both of which 
are available with the full text of this article at 
NEJM.org.
PARTICIPANTS
Pregnant women who had a primary infection at 
5 to 26 weeks of gestation, with a presumed on-
set of infection within the previous 6 weeks, were 
invited to participate in the study. Details regard-
ing the identification of women with recent CMV 
infection, as well as the eligibility criteria, are 
provided in the Supplementary Appendix. The vi-
rology units of Fondazione Istituto di Ricovero e 
Cura a Carattere Scientifico (IRCCS) Policlinico 
San Matteo in Pavia, Italy, and Sant’Orsola Mal-
pighi Hospital in Bologna, Italy, served as the 
reference diagnostic centers for confirmation of 
primary CMV infection.
Randomization
Participants were randomly assigned, in a 1:1 ratio, 
to receive hyperimmune globulin or placebo. 
Randomization was performed with the use of a 
computer-based randomization list that was gen-
erated by the study statistician and provided to 
the study pharmacists by the contract research or-
ganization. Randomization, which was performed 
with the use of Stata software, was balanced in 
blocks of various sizes, with stratification accord-
ing to center. Participants, personnel administer-
ing the study drugs, physicians, technicians, and 
the study statistician were unaware of the study-
group assignments until completion of the study 
and retrospective analysis of the samples.
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA DEGLI STUDI DI MILANO on February 5, 2015. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 370;14 nejm.org april 3, 20141318
The hyperimmune globulin preparation (pur-
chased from Cytotect, Biotest Pharma, which had 
no other role in the study) is a ready-for-use solu-
tion that contains 50 U of anti–CMV IgG antibody 
per milliliter (100 mg of protein of plasma origin 
per milliliter, resulting in ≥95% IgG). The dose 
was 100 U (2.0 ml) per kilogram of body weight 
administered intravenously (see the Supplemen-
tary Appendix for details and for the lot numbers 
of the preparations). The placebo was a 0.9% sa-
line solution and was given intravenously at the 
same dose (2.0 ml per kilogram) as the active drug. 
Infusion bags containing the required volume of 
drug or placebo were prepared at each center by the 
study pharmacist and sealed with aluminum foil. 
Only the randomization number was written on 
the label. Pregnant women received hyperimmune 
globulin or placebo every 4 weeks until 36 weeks 
of gestation, detection of CMV in the amniotic 
fluid (in the case of women who underwent am-
niocentesis), or spontaneous termination of the 
pregnancy. Before each infusion, blood samples 
were obtained for retrospective analysis.
LABORATORY TESTS
Levels of virus-specific IgG and IgM antibodies 
were determined with the use of the ETI-CYTOK-G 
PLUS and ETI-CYTOK-M reverse PLUS ELISAs, 
respectively (DiaSorin), and IgG avidity was de-
termined with the use of the CMV IgG avidity 
test (Radim). Neutralizing antibodies against the 
AD169 strain of CMV in human fibroblasts and 
the VR1814 strain of CMV in epithelial (sponta-
neously arising retinal pigment epithelial [ARPE]-
19) cells were assessed as described previously.12 
Viral DNA in the blood was determined with the 
use of a real-time polymerase-chain-reaction (PCR) 
assay (CMV ELITe MGB Kit, ELITechGroup). Pos-
itive samples with less than 396 IU per milliliter 
were assigned an arbitrary value of 200 IU. Anti-
genemia was determined as described previous-
ly.13 Rapid isolation14 of the virus from amniotic 
fluid or urine samples and real-time PCR analy-
sis of those samples were used for the diagnosis 
of congenital infection. Viral load in placentas 
was determined as described previously.15
CD3+, CD4+, CD8+, CD56+, and CD19+ lym-
phocyte counts were determined at each study 
visit. Surface phenotype (in the case of CD4+ 
and CD8+ lymphocytes) as well as interferon-γ–
producing CMV-specific T cells were determined 
retrospectively by means of flow cytometry, as 
described previously.16
DIAGNOSIS AND DATING OF PRESUMED ONSET  
OF MATERNAL INFECTION
The diagnosis of primary CMV infection was 
based on seroconversion (i.e., an appearance of 
virus-specific antibodies in a previously seroneg-
ative woman) or the concomitant presence of 
CMV-specific IgM antibodies and low IgG avidi-
ty. The onset of infection was established on the 
basis of clinical symptoms, when they were pres-
ent. In the case of asymptomatic seroconversion, 
onset was arbitrarily set midway between the 
time of the last seronegative serum sample and 
the first seropositive serum sample. In addition, 
one or more of the following findings were con-
sidered to be consistent with an onset of infec-
tion less than 6 weeks previously: an IgM value 
that was 10 or more times the cutoff value, IgG 
avidity of less than 15% (avidity of <35% indi-
cates a primary infection acquired <12 weeks 
earlier), or detection of pp65 antigenemia.
STATISTICAL ANALYSIS
We estimated that we would need to enroll 60 
women in each group for the study to have 80% 
power to confirm the reduction in congenital in-
fection from 40% to 16% reported by Nigro et 
al.,5 at a 5% type I error rate and assuming a 10% 
rate of withdrawal. A 36-month enrollment peri-
od was anticipated for recruiting this number of 
patients. The statistical analyses followed the 
intention-to-treat principle for the efficacy end 
points and the on-treatment principle for the 
safety end points. The analysis population con-
sisted of all women who underwent randomiza-
tion and were assessed for the primary end point. 
The incidence of the primary end point was com-
pared between the two study groups with the use 
of Fisher’s exact test, and the difference in risk 
was calculated together with its 95% confidence 
interval. We used Fisher’s exact test to compare 
categorical secondary end points, the Mann–
Whitney U test to compare continuous secondary 
end points, and the log-rank test to compare 
time-to-event secondary end points. A futility 
analysis was planned after half the study par-
ticipants had reached the primary end point, 
with the aim of recommending the discontinua-
tion of the study if the 95% confidence interval 
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for the difference in risk did not include at least 
a 10-percentage-point benefit with the active drug. 
All the analyses were performed with the use of 
Stata 12 software (StataCorp). A two-sided P value 
of less than 0.05 was considered to indicate sta-
tistical significance.
R esult s
ENROLLMENT
Enrollment took place from June 2009 through 
March 2011, and the last newborn was examined 
in November 2011. Of 338 pregnant women who 
received a diagnosis of primary CMV infection, 
181 (54%) were excluded, and 33 of the 157 eli-
gible women (21%) declined to participate in the 
study (Fig. 1). Of the 124 women enrolled, 123 
completed the study and were included in the ef-
ficacy analysis. There were no significant differ-
ences between the two groups in any of the base-
line characteristics, including the method used 
for determining the onset of infection (Table 1).
In both groups, the diagnosis of primary in-
fection based on testing for seroconversion was 
made later during pregnancy than was diagnosis 
based on CMV-specific IgM antibody level and 
IgG avidity (14 weeks [range, 7 to 26] vs. 8 weeks 
[range, 5 to 18] in the hyperimmune globulin 
group and 17 weeks [range, 6 to 26] vs. 8 weeks 
[range, 6 to 17] in the placebo group). Overall, 
124 Underwent randomization
338 Pregnant women with primary CMV
infection were assessed for eligibility
214 Did not undergo randomization
181 Were ineligible
11 Requested hyperimmune globulin
9 Withdrew for logistic reasons
4 Did not want to take drugs
9 Declined to participate without giving a reason
61 Were assigned to hyperimmune globulin 63 Were assigned to placebo
1 Dropped out
61 Were included in efficacy analysis 62 Were included in efficacy analysis
53 Completed the study at delivery
8 Completed the study at amniocentesis
51 Completed the study at delivery
10 Completed the study at amniocentesis
1 Had spontaneous abortion
Figure 1. Enrollment and Outcomes.
The reasons for ineligibility (181 women) were a presumed onset of maternal cytomegalovirus (CMV) infection 
more than 6 weeks before diagnosis (89 women), primary infection acquired either before the 5th week or after the 
26th week of gestation (65), termination of pregnancy within the first trimester (14), autoimmune disease (7), 
thrombotic disorders (2), twin pregnancy (2), and an age of less than 18 years (2). One participant who underwent 
randomization and was assigned to the placebo group did not attend the first scheduled treatment appointment 
and was excluded from the analyses.
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72 of the 123 women with primary infection 
(59%) reported symptoms (45 women), had ab-
normal laboratory findings (13 women, 8 with 
abnormal liver enzyme levels and 5 with lym-
phocytosis), or both (14 women with symptoms 
and abnormal liver enzyme levels) that were com-
patible with primary CMV infection. Fever, as-
thenia, and an influenza-like syndrome, togeth-
er with abnormal liver enzyme levels, were the 
symptoms and signs reported most frequently.
INFUSIONS
A total of 271 infusions were administered in the 
hyperimmune globulin group, and 254 in the 
placebo group. The median number of infusions 
received by each woman did not differ signifi-
cantly between the hyperimmune globulin group 
and the placebo group (5 infusions [interquartile 
range, 3 to 6] and 4 infusions [interquartile range, 
3 to 6], respectively; P = 0.60).
PRIMARY END POINT
Intrauterine transmission occurred in 45 of 123 
cases (37%). Congenital infection was diagnosed 
before birth in 18 fetuses and at birth in 27 new-
borns. Three of the 40 newborns (8%) who had 
tested negative for CMV when amniocentesis was 
performed were found at birth to be infected 
(Fig. 2). A total of 18 congenital infections oc-
curred among the fetuses or newborns of the 61 
Table 1. Baseline Characteristics of the Study Participants.*
Variable
Hyperimmune Globulin
(N = 61)
Placebo
(N = 62)
Age — yr
Median 33 33
Interquartile range 30–35 29–35
Parity — no. (%)
0 20 (33) 18 (29)
≥1 41 (67) 44 (71)
Evidence of infection — no. (%)
IgG seroconversion 44 (72) 44 (71)
IgM antibodies and low IgG avidity 17 (28) 18 (29)
Gestation at onset of maternal infection — wk
Median 12 14
Interquartile range 10–18 8–20
Interval between onset of infection and treatment — wk
Median 5 5
Interquartile range 4–5 4–6
Presence of symptoms or signs — no. (%) 38 (62) 34 (55)
Evidence for dating of presumed onset of infection — no. (%)
Seroconversion and symptoms or signs, plus IgM ratio ≥10,  
avidity <15%, or positive for pp65 antigenemia
24 (39) 16 (26)
Seroconversion without symptoms or signs plus IgM ratio ≥10, 
avidity <15%, or positive for pp65 antigenemia
11 (18) 17 (27)
Seroconversion, with or without symptoms or signs 9 (15) 11 (18)
Avidity <15%, with or without symptoms or signs 10 (16) 12 (19)
IgM ratio ≥10, with or without symptoms or signs 4 (7) 3 (5)
Avidity <15% plus IgM ratio ≥10 or pp65 antigenemia, with or 
without symptoms or signs
3 (5) 3 (5)
* There were no significant differences between the two groups in any of the baseline characteristics.
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women in the hyperimmune globulin group 
(30%), and 27 among the fetuses or newborns of 
the 62 women in the placebo group (44%), for a 
difference of 14 percentage points (95% confi-
dence interval, −3 to 31; P = 0.13). Of the 18 wom-
en in the hyperimmune globulin group who 
transmitted the virus, 9 of the mothers received 
a diagnosis of CMV during the first trimester and 
9 during the second trimester; of the 27 women 
in the placebo group who transmitted the virus, 
12 received a diagnosis of CMV during the first 
trimester and 15 during the second trimester. A 
nonsignificant difference in the transmission 
rate was observed when only fetuses or only new-
borns were included in the analysis and when 
only mothers who underwent seroconversion 
were included. No significant difference between 
the two groups was observed with respect to the 
viral DNA load in the amniotic fluid of infected 
fetuses or with respect to levels of viral DNA in 
urine or blood or virus-specific IgM in infected 
newborns (Table 2).
IMMUNOLOGIC AND VIROLOGIC ANALYSES  
OF MATERNAL BLOOD
No significant difference was observed between 
the two groups with respect to CMV-specific IgG 
and IgM, IgG avidity, or levels of neutralizing 
antibodies (as determined in human fibroblasts 
and ARPE-19 epithelial cells) (Table S1 in the 
62 Women received placebo
Overall transmission rate
27/62 (44%)
26 Underwent
amniocentesis
36 Did not undergo
amniocentesis
15 Had uninfected newborns
19 Had uninfected newborns
17 Had infected newborns
15 Delivered 36 Delivered
16 Had uninfected fetuses
1 Had miscarriage
B
61 Women received hyperimmune
globulin
Overall transmission rate
18/61 (30%)
33 Underwent
amniocentesis
28 Did not undergo
amniocentesis
21 Had uninfected newborns
7 Had infected newborns
22 Had uninfected newborns
3 Had infected newborns
25 Delivered 28 Delivered
25 Had uninfected fetuses
8 Had infected fetuses 10 Had infected fetuses
A
Figure 2. Primary End Point and Overall Transmission Rate.
The primary end point — congenital infection diagnosed at birth or by means of amniocentesis — and the overall rate of maternal trans-
mission of CMV are shown for the group of women who received hyperimmune globulin (Panel A) and the group of women who received 
placebo (Panel B). In the placebo group, one intrauterine death occurred after amniocentesis, and postmortem examination of the fetus 
confirmed the absence of CMV infection. In three women in the hyperimmune globulin group, the absence of congenital infection, assessed 
on the basis of amniocentesis, was not confirmed at birth. In these cases, amniocentesis had been performed at 22, 20, and 22 weeks of 
gestation (6, 8, and 11 weeks, respectively, after the presumed onset of maternal infection).
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Supplementary Appendix). At the time of enroll-
ment, all the women were already positive for 
VR1814-neutralizing antibodies (in epithelial 
cells), whereas AD169-neutralizing antibodies 
(in fibroblast cells) were not detected in 18 of 59 
women (31%) in the hyperimmune globulin 
group or in 20 of 62 women (32%) in the placebo 
group. At study end, all the women in both 
groups were positive for AD169 neutralizing an-
tibodies. The findings with respect to lympho-
cyte subpopulations, CMV-specific cell-mediated 
immunity, and level of CMV DNA in the blood 
were similar in the two groups (Table S1 in the 
Supplementary Appendix), as was the time to 
clearance of viral DNA from the blood (Fig. S1 in 
the Supplementary Appendix).
When the characteristics of women who 
transmitted the virus and those of women who 
did not transmit the virus were compared be-
tween the two study groups and within each 
study group, no significant difference was ob-
served with respect to the week of gestation at 
the onset of infection, the number of weeks be-
tween the diagnosis of infection and treatment 
(Table S2 in the Supplementary Appendix), or 
any of the other immunologic or virologic vari-
ables investigated (Table S3 in the Supplemen-
tary Appendix).
ADVERSE EVENTS
A total of 20 adverse events were reported in 
16 women, including 11 serious adverse events in 
10 women. The serious adverse events in the 
 hyperimmune globulin group were preterm de-
livery (4 women, at 25, 32, 33, and 33 weeks), 
intrauterine growth restriction and induction of 
preterm delivery (1 woman, at 36 weeks), intra-
uterine growth restriction (1 woman), and intra-
hepatic cholestasis of pregnancy and postpartum 
eclampsia (2 events in 1 woman). The serious 
adverse events in the placebo group were sponta-
neous abortion after amniocentesis, arthralgia 
of the upper and lower limbs, and pregnancy-
induced hypertension (1 woman each). Adverse 
events in the hyperimmune globulin group 
 included pruritus of the lower limbs (3 events in 
1 woman), headache (1 woman), and vomiting 
(1 woman). Adverse events in the placebo group 
included asthenia (1 woman), headache (1 wom-
an), and thrombocytopenia (2 events in 1 woman). 
Overall, obstetrical complications (preterm deliv-
ery, preeclampsia, and fetal growth restriction) 
were recorded in 7 of 53 women (13%) in the 
hyperimmune globulin group who remained in 
the study until the time of delivery, as compared 
with 1 of 51 women (2%) in the placebo group 
(P = 0.06).
Table 2. Virologic Findings in CMV-Infected Fetuses and Newborns.
Variable
Mothers Received  
Hyperimmune Globulin
Mothers Received 
Placebo P Value
Fetuses
No. with infection 8 10
Viral DNA in amniotic fluid — log10 copies/ml 0.40
Median 6.8 6.6
Interquartile range 5.20–7.48 6.14–7.09
Newborns
No. with infection 10 17
Positive for viral DNA in blood — no. (%) 10 (100) 15 (88) 0.51
Viral DNA in blood — IU/ml 0.38
Median 1353 925
Interquartile range 200–13,457 200–2061
Viral DNA in urine — log10 copies/ml 1.00
Median 7.39 7.11
Interquartile range 5.91–7.85 6.67–7.62
Positive for IgM — no./total no. tested (%) 4/9 (44) 4/16 (25) 0.39
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CLINICAL OUTCOME IN NEWBORNS
Overall, 104 women remained in the study until 
the time of delivery (Fig. 2). No significant differ-
ences with respect to sex, weight, gestational age 
at birth, or Apgar score were observed between 
newborns whose mothers had received hyperim-
mune globulin and newborns whose mothers 
had received placebo. The most frequent compli-
cation among babies born to mothers who had 
received hyperimmune globulin was prematurity 
(Table 3). Premature birth was recorded in 7 of 
48 babies (15%) born to mothers who had re-
ceived hyperimmune globulin and in 1 of 47 ba-
bies (2%) born to mothers who had received 
placebo (P = 0.06). Six of the 7 premature babies 
born to mothers who had received hyperimmune 
globulin were not infected with CMV. Three in-
fants born to mothers in the hyperimmune glob-
ulin group had a low birth weight (range, 1880 to 
2170 g), and 1 infant had an extremely low birth 
weight (870 g). Three of 10 CMV-infected new-
borns in the hyperimmune globulin group (30%) 
and 4 of 17 in the placebo group (24%) had 
symptoms at birth.
OTHER SECONDARY END POINTS
Preliminary analysis of fetal records indicated 
that there were no significant differences be-
tween the two study groups in ultrasonographic 
findings: 7 of 61 fetuses (11%) in the hyperim-
mune globulin group and 10 of 62 (16%) in the 
placebo group had transient or permanent abnor-
malities. Similarly, the median DNA viral load in 
19 term placentas (10 from mothers in the hyper-
immune globulin group and 9 from mothers in 
the placebo group) did not differ significantly 
between the two groups and was low in both 
groups (10 copies per 0.005 μg [range, 10 to 10] 
and 16 copies per 0.005 μg [range, 10 to 34], re-
spectively).
Discussion
This controlled study did not show a significant 
reduction in the rate of transmission of CMV in-
fection among women receiving hyperimmune 
globulin as compared with women receiving pla-
cebo. Moreover, this study showed no effect of 
hyperimmune globulin on the activity of neutral-
Table 3. Symptoms at Birth in Infected and Uninfected Newborns, According to the Study Treatment Received  
by the Mother.*
Variable
Newborns Whose Mothers 
Received Hyperimmune Globulin
Newborns Whose Mothers 
Received Placebo
Infected
(N = 10)
Uninfected
(N = 38)†
Infected
(N = 17)
Uninfected
(N = 30)†
Prematurity — no.‡ 1 6 1 0
Fetal growth restriction — no.§ 1 2 2 0
Microcephaly — no.¶ 1 2 2 0
Jaundice — no. 1 5 2 2
Hearing deficits — no.‖ 0 2 1 1
Other symptoms or birth defects — no.** 2 4 0 2
≥1 Symptom or birth defect — no. (%) 3 (30) 10 (26) 4 (24) 5 (17)
* There were no instances of hypotonia, petechiae, or hepatosplenomegaly in any of the newborns.
† Only newborns with a known clinical outcome were included.
‡ Premature birth was defined as birth before 36 weeks, 6 days of gestation. The infected infant in each group was born 
at 36 weeks of gestation. The six uninfected infants whose mothers had received hyperimmune globulin were born at 
25, 32, 33, 33, 35, and 36 weeks of gestation.
§ Fetal growth restriction was defined as less than the 10th percentile for weight.
¶ Microcephaly was defined as a head circumference that was less than the 10th percentile.
‖ Hearing deficits were identified on the basis of testing for otoacoustic emissions.
** Among newborns whose mothers had received hyperimmune globulin, the other symptoms or birth defects were  
hypoxemia (1 infant) and fundus oculi abnormalities (1) in infected infants and hypoxemia (2 infants), respiratory dis-
tress (1), and sepsis (1) in uninfected newborns. Among newborns whose mothers had received placebo, the other 
symptoms or birth defects were hypospadias and hydrocele (1 infant) and preauricular skin tags (1); both infants 
were uninfected.
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izing antibodies. Previous data showed that neu-
tralizing antibodies, as measured in endothelial 
or epithelial cells with the use of the VR1814 
CMV prototype, are directed primarily against 
the pentameric gH/gL/pUL128L complex17,18 and 
represent the major neutralizing component of 
human serum and commercial hyperimmune 
globulin.19,20 As confirmed in this study, these 
neutralizing antibodies are produced and peak 
very early after the onset of primary infection, 
without a clear difference between mothers who 
transmit the virus and mothers who do not.12,21 
On the other hand, neutralizing antibodies 
against AD169 are slower to develop,12,21,22 and 
in our study, administration of hyperimmune 
globulin did not significantly modify their levels.
Similarly, hyperimmune globulin did not sig-
nificantly modify maternal levels of DNA in the 
blood or the time to clearance of DNA from the 
blood, nor did it significantly modify DNA levels 
in placentas. No significant differences in the 
level of DNA in the blood were noted in either 
study group between women who transmitted 
the virus and those who did not — a finding 
that was in agreement with results of a previous 
study.23 These findings do not support the ex-
planation that hyperimmune globulin could act 
by reducing the maternal or placental viral load 
through a direct neutralization effect, as hypoth-
esized by Nigro and colleagues.5 Finally, admin-
istration of hyperimmune globulin apparently had 
no effect on the virus-specific T-cell responses.
One challenging aspect of the CHIP study 
was establishing the presumed onset of primary 
infection. Relying on the experience of the two 
reference diagnostic centers, in Pavia and Bolo-
gna,24,25 we defined the onset of primary infec-
tion as the reported date of the onset of symp-
toms or signs when those reports were in 
agreement with serologic results. In this study, 
symptoms and signs were reported by about 
60% of the women. Other studies have shown 
similar rates.26-28 In addition, on the basis of our 
experience with the assays used in this study, 
when the results of serologic tests reached pre-
specified levels (i.e., an IgM ratio higher than 10 
times the cutoff value or IgG avidity lower than 
15%), the onset was assumed to have occurred 
during the previous 6 weeks. CMV antigenemia 
was another criterion, since its detection is re-
stricted to the early phase of primary infection 
in immunocompetent persons.29 Altogether, the 
above criteria were considered to be strict enough 
to reasonably exclude infections acquired earlier 
than 6 weeks before enrollment.
Another critical point was that we excluded 
from our analysis infections that occurred be-
fore conception, since the risk of fetal infection 
associated with maternal infection acquired be-
fore pregnancy is lower than that reported after 
primary infection during the first trimester of 
gestation (approximately 5% vs. approximately 
40%).24,30,31 We excluded those infections by re-
stricting the enrollment to women with primary 
infection acquired after the fifth week of preg-
nancy. In the study by Nigro et al,5 the median 
week of gestation at the time of maternal infec-
tion was significantly earlier in the group of 
women who received prophylactic hyperimmune 
globulin treatment than in the group of women 
who did not receive hyperimmune globulin (14 
weeks vs. 20 weeks) (P<0.01), and the rate of 
transmission was significantly lower among the 
pretreated women as well.
In this study three cases of false negative pre-
natal diagnosis were observed in the hyperim-
mune globulin group. False negative results have 
been reported previously.32,33
A recent preliminary evaluation of the safety 
and efficacy of standard preparations of intrave-
nous immune globulin in pregnant women with 
primary CMV infection showed an increase in 
CMV IgG titers and avidity.34 In that study, 27 of 
67 newborns (40%) born to mothers who had 
been treated with intravenous immune globulin 
were found to be infected at birth. However, it is 
not clear whether the lower preventive efficacy 
of standard immune globulin as compared with 
hyperimmune globulin is due to differences be-
tween study protocols or immune globulin prep-
arations.35
Finally, a higher number of serious adverse 
events were recorded among women who received 
hyperimmune globulin and among their new-
borns than among women who received placebo 
and their newborns. The administration of intra-
venous immune globulin can have adverse ef-
fects. Fortunately, most adverse events have been 
mild.36 Although the higher rate of preterm de-
liveries observed among women in the hyperim-
mune globulin group raises some concerns, at 
the moment there is no definitive indication that 
preterm birth is a hyperimmune globulin–related 
adverse event.
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From the cost-effectiveness point of view, our 
results (a 32% relative decrease in the transmis-
sion rate and no significant difference in the 
clinical outcome at birth) represent less than the 
47% reduction in congenital CMV that has been 
considered by some to be the threshold for rec-
ommending screening for and treatment of pri-
mary maternal infection in pregnancy as a cost-
effective strategy.37
Currently, two randomized, phase 3 studies 
of the prevention of congenital infection are 
under way. One, sponsored by Biotest, is being 
conducted in Europe,38 and the second, sponsored 
by the Eunice Kennedy Shriver National Institute 
of Child Health and Human Development, is 
ongoing in the United States (ClinicalTrials.gov 
number, NCT01376778). The hope is that the 
results of these studies will further our under-
standing of the efficacy and safety of hyperim-
mune globulin administration as a means of 
preventing congenital CMV infection.
In conclusion, this randomized, placebo-con-
trolled trial of virus-specific hyperimmune globu-
lin for the prevention of congenital CMV infection 
showed no significant between-group difference 
in either the primary outcome or the secondary 
clinical and biologic outcomes examined. How-
ever, because the effect was smaller than expected, 
the power to detect such a difference was small 
(33%). About three times as many patients would 
have had to have been enrolled for the study to 
have had the power to detect a 14-percentage-point 
difference in the primary outcome.
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